Banned in EU

Rh-Oligopeptide-2

A cosmetic ingredient used as skin protecting in skincare, haircare, and personal-care products sold in the European Union.

What is it?

rh-Oligopeptide-2 is a single chain recombinant human peptide, produced by fermentation in E. coli. The starting gene is directly isolated from a human cell which codes for Insulin-Like Growth Factor. It contains a maximum of 153 amino acids which may contain disulfide bonds and/or sugar. The protein consists of the proper sequence of the standard amino acids. Human Oligopeptide-2; IGF-1; Insulin Like Growth Factor; Somatomedin C

What does it do?

Rh-Oligopeptide-2 is listed in the EU cosmetic ingredient inventory with the following declared functions:

EU regulatory status

This ingredient is banned in the European Union.

Rh-Oligopeptide-2 is listed under Annex II of EU Cosmetics Regulation 1223/2009 (entry 416), making it prohibited in cosmetic products placed on the EU market.

Frequently asked questions

What is Rh-Oligopeptide-2?

Rh-Oligopeptide-2 is a cosmetic ingredient catalogued in the EU CosIng database. rh-Oligopeptide-2 is a single chain recombinant human peptide, produced by fermentation in E. coli. The starting gene is directly isolated from a human cell which codes for Insulin-Like Growth Factor. It contains a maximum of 153 amino acids which may contain disulfide bonds and/or sugar. The protein consists of the proper sequence of the standard amino acids. Human Oligopeptide-2; IGF-1; Insulin Like Growth Factor; Somatomedin C

Is Rh-Oligopeptide-2 allowed in cosmetics in the EU?

No. Rh-Oligopeptide-2 is banned for use in cosmetic products in the EU under Annex II of Regulation 1223/2009.

What does Rh-Oligopeptide-2 do in cosmetic products?

Rh-Oligopeptide-2 is declared in the EU cosmetic ingredient inventory with these functions: skin protecting.

What is the CAS number of Rh-Oligopeptide-2?

The CAS (Chemical Abstracts Service) number for Rh-Oligopeptide-2 is -.

Related ingredients

Source: EU CosIng database (European Commission). This page is derived from public-sector information published by the European Commission. · Last updated: 04/03/2011